WO2004052828A1 - (4e)−5−クロロ−2−イソプロピル−4−ペンテン酸エステルおよびその光学活性体の製造方法 - Google Patents
(4e)−5−クロロ−2−イソプロピル−4−ペンテン酸エステルおよびその光学活性体の製造方法 Download PDFInfo
- Publication number
- WO2004052828A1 WO2004052828A1 PCT/JP2003/015694 JP0315694W WO2004052828A1 WO 2004052828 A1 WO2004052828 A1 WO 2004052828A1 JP 0315694 W JP0315694 W JP 0315694W WO 2004052828 A1 WO2004052828 A1 WO 2004052828A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- isopropyl
- reaction
- represented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/333—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
- C07C67/343—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
- C07C67/32—Decarboxylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Definitions
- the present invention relates to a method for producing (4E) -5-clo-2--2-isopropyl-14-pentenoate, which is useful as an intermediate for agricultural chemicals or pharmaceuticals.
- the present invention also relates to a method for producing (S)-(4E) -5_chloro-2-isopropyl-4-monopentenoate, which is an optically active substance particularly useful as an intermediate for pesticides or pharmaceuticals.
- Methyl isopentanoate is reacted with 1,3-dichloro-1-propene at very low temperature (-78) in the presence of lithium diisopropylamide (LDA) to give 5-cyclopent-2-isopropyl-4-pentenoate.
- LDA lithium diisopropylamide
- Racemic (4E) -5 obtained by hydrolyzing racemic (4E) -5-chloro-2-isopropyl-14-penteneethyl ester obtained by the method of (2)
- the diastereomer salt of the (S) form is separated by reacting the optically active cinchonidine with —clone—2-isopropyl—4-pentenoic acid to obtain a diastereomer monosalt and then recrystallizing it. Then, a method of obtaining (S) -1- (4E) -5-chloro-2-isopropyl-4_pentenoic acid by acid treatment (see WO 01/09079 pamphlet).
- the present invention has been made to solve the above problems, and provides a method for producing (4E) -5-chloro-2-isopropyl-4-pentenoate using inexpensive raw materials and reagents. .
- the method of the present invention can be carried out by a simple reaction, is a method applicable to industrial mass production, and can selectively produce E-isomer in high yield.
- the present invention provides the following inventions.
- base (II) is The method according to ingredients 1> is a metal alkoxide of the formula M 2 OR 2 (however, M 2 represents a N a or K, the R 2 is a lower alkyl group Shown.)
- aprotic solvent (I) is toluene, xylene, benzene, heptane, dimethylformamide, dimethylacetamide, N-methylpyrrolidinone, dimethyl sulfoxide, diethylene glycol dimethyl ether, tetrahydrofuran, t-butyl methyl ether and sulfolane
- (4E) 5-chloro-1--2-isopropyl-14-pentenoate represented by formula (4) obtained by the production method according to any one of ⁇ 12> ⁇ 1> to ⁇ 11>
- the compound represented by the formula (1) is also referred to as a compound (1).
- the outline of the production method of the present invention can be represented by the following formula.
- the present invention is not limited to the following formula.
- step (a) a step of obtaining a compound (2) by reacting with a base (I) in an aprotic solvent (I) and then reacting with an isopropyl halide (hereinafter referred to as step (a)) .
- I do Compound (2) is reacted with base (II) in the presence of aprotic solvent (II), and then reacted with (1E) -11,3-dichloro-1-propene to give compound (2).
- Step 3) is obtained (hereinafter referred to as step (b)).
- a step of obtaining a compound (4) by dealkoxycarbonylating one of the esters hereinafter, referred to as a step (c)
- a step (d)) of obtaining the compound (5) in the (S) form is performed.
- R represents a lower alkyl group or an aralkyl group.
- the lower alkyl group means an alkyl group having 1 to 4 carbon atoms, such as a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an iso-alkyl group.
- the aralkyl group refers to a lower alkyl group substituted by an aryl group, and is preferably a lower alkyl group substituted by one or two aryl groups.
- the aryl group include a phenyl group, a 1-naphthyl group, and a 2-naphthyl group.
- the aryl group may have one or more substituents on its ring. As such a substituent, a lower alkyl group is preferable.
- the aralkyl group include a benzyl group and a diphenylmethyl group. As R, a lower alkyl group is preferable, and a methyl group is particularly preferable.
- metal hydrides, metal alkoxides, lithium diisopropylamide (LDA), lithium hexamethyldisilazide, pyridine, triethylamine, inorganic bases and the like can be used.
- LDA lithium diisopropylamide
- pyridine lithium hexamethyldisilazide
- triethylamine inorganic bases and the like
- metal alkoxide represented by the formula M 1 OR 1 as the base (I) because of its good reactivity, good operability, and excellent economical efficiency.
- the metal alkoxides represented by the formulas M 1 OR 1 and M 2 OR 2 include sodium methoxide (NaOCH 3 ) and sodium ethoxide (Na ⁇ C
- the metal alkoxide represented by the formula M 1 OR 1 is preferably a solution of an alcohol represented by the formula R 1 OH, and a metal represented by the formula M 2 OR 2
- the alkoxide has the formula R 2 OH It is preferably an alcoholic solution (provided that M 1 , M 2 , R 1 and R 2 have the same meanings as described above).
- the concentration is preferably from 5 to 35% by mass, particularly preferably from 15 to 35% by mass.
- those metal alkoxides prepared at the time of use from an alkali metal and a lower alcohol may be used. Compared to bases such as LDA and NaH used in conventional methods, these metal alkoxides have the advantage that they are easier to use because they have better operability and lower costs.
- aprotic solvents (II) include aromatic hydrocarbon solvents such as toluene, xylene and benzene; aliphatic hydrocarbon solvents such as hexane and heptane; dimethylformamide (DMF), dimethylacetate Amide solvents such as amide (DMA) and N-methylpyrrolidinone (NMP); sulfoxide solvents such as dimethyl sulfoxide (DMSO); sulfone solvents such as sulfolane; diethylene glycol dimethyl ether (DME), diglyme, tetrahydrofuran ( Ether solvents such as THF) and t-butyl methyl ether (TBME).
- aromatic hydrocarbon solvents such as toluene, xylene and benzene
- aliphatic hydrocarbon solvents such as hexane and heptane
- DMF dimethylformamide
- Amide solvents such as amide (DMA) and N-methylpyrroli
- solvents may be used alone or as a mixed solvent of two or more.
- aprotic solvents (I) and (II) in the present invention toluene and an amide-based solvent or sulfolane are used because they can suppress generation of impurities, have good operability, and can recover and reuse the solvent.
- the mixing ratio of (amide-based solvent or sulfolane) to toluene is (amide-based solvent or sulfolane) Ztoluene (volume ratio), preferably 1 to 2/1/50, and particularly preferably 1Z3 to: LZ10.
- dimethyl malonate, getyl malonate, diisopropanol pill and the like can be used, and dimethyl malonate is preferably used.
- halogenated isopropyl isopropyl bromide, isopropyl chloride, isopropyl chloride and the like can be used.
- Malonic acid diester, isopropyl halide, and (1E) -1,3-dichloro-1-propene are known compounds and are industrially inexpensively available compounds. It is usually preferable to use commercially available products of these compounds. Commercial products may be purified if necessary. However, it can be used without purification in normal cases.
- Step (a) is a tertiary alkylation step in which compound (1) is reacted with base (I) in aprotic solvent (I) and then reacted with isopropyl halide to obtain compound (2). is there.
- the amount of the isopropyl halide is preferably at least 1 mol, more preferably from 1.0 to 55.0 mol, per mol of the compound (1) from the viewpoint of the conversion and the yield of the reaction, In view of operability, volumetric efficiency, and cost, 1.0 to 3.0 times mol is particularly preferable.
- isopropyl halide isopropyl bromide is preferred from the viewpoint of reactivity and cost.
- the amount of the base (I) is preferably 9 to 5 moles, more preferably 1.0 to 3.0 moles, based on the compound (1).
- the amount of the aprotic solvent (I) is preferably 0.5 to 20 ml based on 1 g of the compound (1).
- metal iodides such as sodium iodide (Na I) and potassium iodide (KI), or sodium bromide (NaBr) and potassium bromide (KBr) are used to further enhance the reactivity.
- metal iodides or metal bromides are added, the amount thereof is preferably from 1 mol% to 100 mol%, especially from 1 mol% to 10 mol%, based on the isopropyl halide. preferable.
- the reaction temperature in the step (a) is preferably from +30 to +180, particularly preferably from +70 to +140.
- the reaction time is preferably 1 to 30 hours.
- the reaction pressure is preferably atmospheric pressure or pressurization, and particularly preferably atmospheric pressure.
- step (a) the compound (1), the base (I) and the halogenated isoprene pill are added in this order (a-1), or the base (I), the compound (1) and the isopropyl halide are added. It is preferable to carry out the reaction by a method (a-2) of adding the above in this order.
- the base (I) in the step (a) it is preferable to use a base represented by the above formula M 1 OR 1 (M 1 and R 1 have the same meanings as described above).
- the compound (1) can be prepared in the presence of the aprotic solvent (I) according to the method (a-1) or the method (a_2). It is preferred to react with the base and then with isopropylpropyl halide.
- an alcohol represented by the formula R 1 OH is by-produced.
- Na ⁇ CH 3 is used as a base
- methanol is by-produced
- Na ⁇ C 2 H 5 is used, ethanol is by-produced.
- the alcohol When the alcohol is by-produced, it is preferable to remove the alcohol from the reaction system before reacting with the isopropyl alcohol.
- a method for removing alcohol a method by distillation is preferable, and usually, it is preferable to distill by heating before adding isopropyl halide.
- the reaction proceeds even if the protic solvent such as alcohol produced as a by-product remains in the reaction system. However, it is preferable to remove the solvent from the viewpoints of conversion, reaction time, and the like.
- the isopropyl halide in the step) be used in an amount of 1 mole or more based on the compound (1). In this case, it is preferable to remove the isopropyl halide from the reaction system after the completion of the reaction.
- a side reaction of the isopropyl halide to quaternary alkylate the compound (2), and a formula M 2 OR such as Na OCH 3 with isopropyl halide are performed.
- the reaction with the base represented by 2 occurs, and the yield of the compound (3), which is the target product of the step (b), is reduced, so that it is preferable. Absent.
- the amount of the isopropyl halide relative to the compound (2) is preferably set to 5 mol% or less, particularly preferably 1 mol% or less.
- the removed halogenated isopopene pill can be reused again in the reaction of the step (a).
- step (b) the compound (2) is reacted with a base (II) in the presence of an aprotic solvent (II), and then reacted with (IE) -1,3-dichloro-1-propene to give a compound.
- step (b) the compound (2) is reacted with a base (II) in the presence of an aprotic solvent (II), and then reacted with (IE) -1,3-dichloro-1-propene to give a compound.
- step (b) the compound (2) is reacted with a base (II) in the presence of an aprotic solvent (II), and then reacted with (IE) -1,3-dichloro-1-propene to give a compound.
- step (b) the compound (2) is reacted with a base (II) in the presence of an aprotic solvent (II), and then reacted with (IE) -1,3-dichloro-1-propene to give a compound.
- the amount of (IE) -1,3-dichloro-1-propene is preferably 0.9 to 50.0 times the mol of the compound (2), and the operability, volumetric efficiency, The molar ratio is more preferably 1.0 to 3.0 times from the viewpoint of the strike.
- (1E) -1,3-Dichloro-1-propene may be collected and reused in step (b) when excessively used.
- the amount of the base (II) is preferably 0.9 to 5 moles, more preferably 0.9 to 3.0 moles, relative to the compound (2). If the amount of the base (II) is too large, a side reaction may occur in which the unreacted base (II) immediately reacts with (1E) —1,3-dichloromethane—1_propene.
- the aprotic solvent (II) is preferably used in an amount of 0.5 to 20 ml per 1 g of the compound (2).
- a metal iodide such as Na I or KI, or a metal bromide such as NaBr or KBr may be added to further enhance the reactivity.
- the amount thereof is preferably 1 mol% to 100 mol%, and particularly preferably 1 mol%, based on (1E) -1,3-dichloro-1-propene. % To 10 mol%.
- the reaction temperature in the step is preferably +30 t: to +180, particularly preferably +70 to +140.
- the reaction time is preferably 1 to 30 hours.
- the reaction pressure is preferably atmospheric pressure or pressurized, and particularly preferably atmospheric pressure.
- the compound (2), the base (II), and (1E) —1,3-dichloro-1-propene are added in this order (b—1), or the base (11), the compound It is preferable to carry out the reaction by the method (b-2) of adding (2) and (1E) -1,3-dichloromethane_1-propene in this order.
- the base (II) in the step (b) it is preferable to use a base represented by the above formula M 2 OR 2 (where M 2 and R 2 have the same meanings as described above).
- the compound (2) is converted to the compound (2) in the presence of the aprotic solvent (II) according to the method (b-1) or the method (b_2). It is preferred to react with a base and then with (1E) -1,3-dichloro-11-propene.
- an alcohol represented by the formula R 2 OH is by-produced.
- the reaction proceeds even when the protic solvent such as alcohol produced as a by-product remains, but from the viewpoints of conversion, reaction time, etc., (1E) —1,3-dichloromethane—1-propene
- the step (b) is carried out immediately after the step (a)
- the compound (2) produced in the step (a) is isolated and purified. It is preferable to carry out the reaction continuously in the same reactor without any treatment. That is, after the compound (2) is obtained in the step (a), it is preferable to carry out the reaction in the step (b) of obtaining the compound (3) in the same reaction vessel.
- step (a) and step (b) are performed consecutively in the same reaction vessel, the reaction time can be shortened and the operation is easy, which is advantageous in industrial production. .
- the steps (a) and (b) are performed continuously, the isopropyl halide remaining in the reaction of the step (a) reacts with the isopropylmalonic diester (formula 2) in the step (b). For this reason, the yield of the (b) process may decrease.
- the step (c) is performed after the step (b).
- step (c) one of the esters of the compound (3) is subjected to dealkoxycarbonylation to give (4E) —5-chloro-1-2 -— ⁇ -dipropyl-14-pentenoate represented by the formula (4).
- This is a step of dealkoxycarbonylation.
- dealkoxycarbonylation refers to a reaction in which an ester moiety (one COOR moiety) in a compound is removed and replaced with a hydrogen atom.
- the dealkoxycarbonylation step is preferably performed by a method of heating in a polar solvent in the presence of water and an inorganic salt.
- the inorganic salt that can be used is preferably an alkali metal halide, and examples thereof include sodium chloride (NaC 1), lithium chloride (L i C 1), and sodium bromide (NaBr). N a C 1 or L i C 1 is preferred.
- the amount of the inorganic salt is preferably 0.5 to 50-fold the molar amount of the compound (3), Particularly preferred is a mole of up to 10 times.
- the amount of water used in the step (c) is preferably 0.1 to 50 times, more preferably 0.1 to 3 times, the mole of the compound (3).
- the polar solvent examples include amide solvents such as DMF, DMA and NMP, sulfoxide solvents such as DMSO, sulfone solvents such as sulfolane, and ether solvents such as DME and THF.
- the polar solvent may be used alone or as a mixed solvent of two or more. Sulfolane is preferred as the polar solvent because it has good reactivity, can suppress decomposition of the polar solvent itself during the reaction, and has a boiling point suitable for the operation.
- the amount of the polar solvent is preferably from 2 to 30 times, more preferably from 5 to 15 times, the mass of the compound (3).
- the compound (2) produced in the step (a), the compound (3) produced in the step (b), and the compound (4) produced in the step (c) are respectively used for the purpose. It is preferable to perform a corresponding post-treatment and / or purification treatment.
- treatment method 1 water or saline is added to the crude reaction solution, and then water-insoluble such as dichloromethane, toluene, ethyl acetate, butyl acetate, t-butyl methyl ether, diisopropyl ether, or getyl ether is added. Separation by adding a neutral organic solvent, concentration of the organic layer, and further distillation to isolate the target compound.
- Treatment method 2 The organic layer in the treatment method 1 was washed with water and water or brine. Thereafter, a method of concentrating the organic layer and distilling the target compound by distillation, (Processing Method 3) a method of cooling the reaction crude liquid and then performing distillation under reduced pressure, and the like. Further, before and after each of the treatment methods 1 to 3, filtration may be performed, if necessary, and an adsorbent such as activated carbon may be added. In particular, when an adsorbent is added to the product of the step (c), it is preferable because tar-like substances and the like that can be contained in the reaction product can be removed well.
- adsorbent such as activated carbon
- (4E) -5-chloro-2-isopropyl-4-pentenoate (formula 4) obtained by the production method of the present invention is a known compound useful as an intermediate for agricultural chemicals or pharmaceuticals.
- Compound (4) is a compound particularly useful as an intermediate for insecticides and hypertension therapeutics (WO01 / 9079).
- the compound (4) obtained by the above method is usually in a racemic form, and may be subjected to optical resolution (step (d)) as necessary. I can.
- the step (d) is an optically active (S) — (4E) by optically resolving the (4E) -5-chloro-2-4-isopropyl-14-pentenoate represented by the formula (4).
- 5-—Mouth This is the process to obtain 2-isopropyl-14-pentenoic acid ester (Formula 5).
- Method (d-1) Compound (4) is hydrolyzed to a carboxylic acid in a racemic form, then reacted with an optically active base to form a diastereomer salt, and then recrystallized to obtain the required diastereomer. Separate the salt. Next, a method in which an acid is allowed to act on the separated diastereomer to release a carboxylic acid, and the obtained carboxylic acid is further esterified.
- Method (d-2) A method of separating compound (4) using an optical isomer separation column to obtain the required optically active form.
- Method (d-3) A method in which lipase or esterase is allowed to act on compound (4) to selectively hydrolyze one of the optical isomers to obtain a required optically active ester.
- optically active base in the method (d-1) cinchonidine, phenethylamine and the like can be used.
- a method of fractionation by high performance liquid chromatography using a column for separating optical isomers can be adopted, and among them, the SMB method (Simulated Moving Bed method) can be used.
- the method of fractionation is preferred.
- the lipase or esterase can use enzymes used in reagents, pharmaceuticals, and industrial uses.
- an enzyme acting on the (R) form of compound (4) is employed as the enzyme in method (d-3)
- the enzyme acts on the (R) form of compound (4) to hydrolyze it.
- an optically active compound (6) is produced.
- compound (5) which is the (S) form of compound (4) hydrolysis does not occur.
- the optically active compound (5) and the optically active compound (6) are formed in the reaction solution after the enzymatic reaction.
- Compound (5) and compound (6) can be separated by a separation method utilizing the difference in properties between the —COOR group in compound (5) and the —COOH group in compound (6). 5) Retrieve Optical splitting.
- a lipase may be an enzyme derived from yeast (Candida an tarctica), and an esterase may be an enzyme derived from bushu liver (Porcine liver).
- an esterase derived from bushu liver for example, Johnston (John st on DBR) et al., Journal of American Chemical Society (J. Am. Chem. Soc.), 1978, No. 100 Enzymes used in the optical resolution method, Vol.
- an enzyme gene isolated from these lipases or esterases may be incorporated into various vectors, and the expressed protein may be used as an enzyme in the method (d-3).
- the lipase or esterase may be immobilized on an inert carrier from the viewpoint of operability.
- the inert carrier include celite, porous glass beads, cellose and its derivatives, chitin and its derivatives, calcium alginate, ⁇ -carrageenan, polystyrene and its derivatives, polyurethane, polyacrylamide, nylon, and polyvinyl.
- Alcohol, polyethylene glycol derivatives, polypropylene glycol derivatives, or polybutadiene derivatives are preferred, and porous glass beads, chitin and its derivatives, or calcium alginate are particularly preferred.
- the amount of the lipase or esterase to be used can be determined by the hydrolysis activity on the compound (4), which is a raw material for optical resolution. Usually, in terms of reaction rate, the compound
- a solvent may be used as necessary, and it is preferable to use a solvent because of good operability.
- a solvent an aqueous solvent, an organic solvent and a mixed solvent thereof can be used, and it is preferable to use an aqueous solvent since the compound (5) can be obtained with high yield and high e e.
- the solvents may be used alone or as a mixed solvent of two or more.
- a mixed solvent of two or more a mixed solvent of an aqueous solvent and an organic solvent is preferable.
- the amount of the solvent is preferably from 1 to 50% by mass, and particularly preferably from 1 to 30% by mass, based on the compound (4).
- aqueous solvent examples include water and a buffer.
- the buffer may be selected from commonly used buffers. Examples include a phosphate buffer, a citrate buffer, a HEPS buffer, a TRIS buffer, an acetate buffer, and a MES buffer.
- the organic solvent can be appropriately selected from common organic solvents.
- alcoholic solvents such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, and t-butyl alcohol
- aliphatic hydrocarbon solvents such as pentane, hexane, and heptane
- benzene Aromatic hydrocarbon solvents such as toluene, xylene, etc .
- Halogenated hydrocarbon solvents such as methylene chloride, chloroform, and carbon tetrachloride
- getyl ether, diisopropyl ether, t-butyl methyl ether, tetraethyl Ether solvents such as lahydrofuran and dioxane
- ketone solvents such as acetone, methyl ethyl ketone and methyl isobutyl ketone
- other solvents such as acetonitrile, N, N-di
- ester solvent when used, the enzyme may act on the solvent itself. Therefore, it is preferable to select and use an ester solvent that does not act on the enzyme. Further, transesterification between the ester solvent and the raw material is performed. Since the reaction may occur, it is preferable to select and use an ester solvent that does not cause transesterification.
- organic solvents may be used alone or as a mixed solvent of two or more.
- the optical resolution is carried out by the method (d-3), it is usually preferable to carry out the optical resolution by adding the compound (4) to a solution obtained by adding the enzyme to a solvent.
- the compound (4) may be added to the reaction system all at once or continuously, and in the production method of the present invention, it is preferable to add continuously.
- the compound (6) which is an optically active carboxylic acid is produced.
- the carboxylic acid has a strong denaturing effect on the enzyme, and when the concentration of the carboxylic acid in the reaction system increases and the contact time between the carboxylic acid and the enzyme increases, the enzyme activity tends to decrease.
- continuous addition is a concept for “batch addition” in which the entire amount of compound (4) is added all at once in the initial stage of the reaction, and after the reaction of compound (4) is started, the compound is added.
- (4) refers to the operation of adding at least once to the reaction system.
- the continuous addition is performed by introducing an arbitrary amount of the compound (4) into the reaction system at least twice after the start of the reaction, or by introducing the compound (4) for a certain period of time after the enzyme is added to start the reaction. It is preferable to carry out the operation by a continuous operation or the like. The above operation may be performed once or twice or more during the reaction.
- the compound (4) is directly added to the solution obtained by adding the enzyme to the solvent while stirring, or the compound (4) is added. Is added to a solution in which is dissolved in a solvent.
- the means for adding the compound (4) or a solution thereof is not particularly limited, and examples thereof include an air pressure, a pump, and a natural solution.
- the average addition rate of compound (4) is not particularly limited, and is preferably 0.005 to 0.1 mol per hour, more preferably 0.01 to 0.05, per 1 mg of the enzyme present in the reaction system. Mol Z1 hours.
- the addition rate is constant You may let it.
- the time required for adding the compound (4) is not particularly limited as long as it is within an industrially acceptable time. Preferably it is 4 to 30 hours, more preferably 5 to 20 hours.
- the total amount of the compound (4) to be added is not particularly limited, and the total concentration of the compound (4) (the total amount of the compound (4) to the sum of the total amount of the solvent and the total amount of the compound (4)) is 0.1.
- the amount is preferably 60 to 60% by mass, and more preferably 1 to 50% by mass in view of production on an industrial scale.
- the enzymatic reaction in step (d) is usually performed while controlling reaction conditions such as reaction temperature and pH of the reaction solution.
- the reaction conditions can be determined as appropriate in consideration of conditions such as enzymatic reactions, racemization of reaction products, and formation of by-products.
- the reaction temperature is usually preferably from ⁇ 20 to 190, more preferably from 0 to 160, and particularly preferably from 25 to 45, from the viewpoint of the reaction rate.
- the pH of the reaction solution is preferably from 1 to 10, particularly preferably from 3 to 9, and particularly preferably from 7.5 to 8.5, from the viewpoint of the reaction rate and the purity of the compound (5) obtained. .
- the compound (6) is generated in the reaction system as described above, so that the pH of the reaction solution may be out of a preferable range.
- an aqueous solution of an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide, or an aqueous solution of an alkali metal carbonate such as sodium carbonate or potassium carbonate, or an inorganic base such as an aqueous ammonia solution is used as a reaction solution. It is preferable to adjust the pH of the reaction solution by adding to the reaction mixture.
- the reaction time is not particularly limited as long as the activity of the enzyme is maintained and the reaction proceeds. Usually, considering industrial production, the reaction time is preferably 1 hour to 10 days, more preferably 1 to 96 hours, after completion of the continuous addition operation.
- the compound (5) produced in the step (d) is preferably subjected to post-treatment and / or purification according to the purpose.
- a water-insoluble organic solvent eg, hexane, ethyl acetate, t-butyl methyl ether, methylene chloride, chloroform, getyl ether, etc.
- a water-insoluble organic solvent eg, hexane, ethyl acetate, t-butyl methyl ether, methylene chloride, chloroform, getyl ether, etc.
- the compound (5) is extracted into a water-insoluble organic solvent by the above-mentioned extraction operation, and the compound (6) (when the above-mentioned pH adjustment operation is performed, the compound (6) and / or the compound (7)) Remains in the aqueous solvent layer (where M represents an alkali metal atom or NH 4 ).
- the water-insoluble organic solvent layer is preferably washed with an aqueous solution of an alkali metal carbonate (preferably, a 5% sodium carbonate solution). By the washing operation, the compound (6) contained in the water-insoluble organic solvent layer is washed. ) Can be removed.
- compound (5) can be isolated by depressurizing and concentrating or distilling the water-insoluble organic solvent layer. The isolated compound (5) can be further purified, if necessary, by a method such as distillation.
- the aqueous solvent layer after the extraction operation contains the compound (6) and the compound (7).
- the aqueous solvent layer containing the compounds (6) and Z or the compound (7) is made acidic (preferably, pH 4 or less) using hydrochloric acid or the like, and then the aqueous solvent layer is made into a water-insoluble organic solvent.
- a water-insoluble organic solvent e.g, hexane, ethyl acetate, t-butyl methyl ether, methylene chloride, chloroform, getyl ether, etc.
- Compound (6) can be recovered by concentrating the solvent layer.
- the recovered compound (6) can be recovered and reused in the step (d) by esterification by reacting with the alcohol compound represented by the formula ROH in the presence of sulfuric acid, followed by racemization (where R is It has the same meaning.)
- a preferred embodiment of the production method of the present invention includes a method for producing the following compound (5a). That is, the compound (la) is isopropylated to give a compound (2a), which is then reacted with (IE) -1,3-dichloro-1-propene to give the compound
- gas chromatography is referred to as GC, and the amount of the enzyme used is indicated by "Unit s".
- 1 Unit is defined as the enzyme activity that produces 1 imo 1 of butyric acid per minute from 1 wmo 1 of ethyl butyrate at pH 8.0 and +25.
- the structure of the obtained compound was determined by comparison with known data. The optical purity and the optical excess were measured by GC using a Lipodex E5OmX 0.25 mm (available from Macherey-Nagel 1) as a column.
- the system was cooled to 80 to 90, and a toluene solution (375 ml) of isopropyl bromide (264.8 g) was added.
- the mixture was heated and stirred for 20 hours as it was, and after confirming that the raw materials had almost disappeared by GC, methanol (200 ml) was added, and the mixture was gradually heated to remove the remaining isopropyl bromide.
- methanol 200 ml
- methanol 200 ml
- a 28% solution of Na318CH 3 in methanol (318.4 g) was added dropwise, and toluene (600 ml) was added, followed by gradual heating as before to remove methanol.
- the distillate obtained by heating was analyzed by GC, and the heating was stopped when the amount of methanol in the distillate became 0.5% or less.
- Phosphate buffer pH 7.0, 5 mmo 1/23 OmL was added to bushu liver-derived esterase (Roche Diagnostics).
- optical purity of (S)-(4E) -5-chloro-1- (2-propyl) -4-pentenoate methyl ester was less than 90% e e.
- (4E) -5-chloro-2-isopropyl-4-pentenoate which is useful as an intermediate for pesticides or pharmaceuticals in a short process without conversion to isomers is selected.
- the present invention provides a method for producing a target in a high yield. By optically resolving the (4E) -5-chloro-2-isopropyl-4-pentenoate ester obtained by the above method, it is more useful as an intermediate for pesticides or pharmaceuticals.
- the production method of the present invention is economical because it can be carried out using reagents that are cheaper and easier to use than conventional methods. Further, the production method of the present invention can be carried out without using a special reaction apparatus, and the yield of the reaction is very high, so that it is a useful method as an industrial production method.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES03777366.0T ES2281675T5 (es) | 2002-12-09 | 2003-12-09 | Procedimiento para producir un ester (4E)-5-cloro-2-isopropil-4-pentenoato y un isómero ópticamente activo de este ester |
JP2005502360A JP4645986B2 (ja) | 2002-12-09 | 2003-12-09 | (4e)−5−クロロ−2−イソプロピル−4−ペンテン酸エステルおよびその光学活性体の製造方法 |
DE60312214.0T DE60312214T3 (de) | 2002-12-09 | 2003-12-09 | Verfahren zur herstellung von(4e)-5-chloro-2-isopropyl-4-pentensäureester und optischaktivem isomer davon |
EP03777366.0A EP1571138B2 (en) | 2002-12-09 | 2003-12-09 | Processes for producing (4e)-5-chloro-2-isopropyl-4-pentenoic ester and optically active isomer thereof |
AU2003289250A AU2003289250A1 (en) | 2002-12-09 | 2003-12-09 | Processes for producing (4e)-5-chloro-2-isopropyl-4-pentenoic ester and optically active isomer thereof |
CA2507944A CA2507944C (en) | 2002-12-09 | 2003-12-09 | Process for producing (4e)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof |
US11/147,255 US7232925B2 (en) | 2002-12-09 | 2005-06-08 | Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-356651 | 2002-12-09 | ||
JP2002356651 | 2002-12-09 | ||
JP2003143256 | 2003-05-21 | ||
JP2003-143256 | 2003-05-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/147,255 Continuation US7232925B2 (en) | 2002-12-09 | 2005-06-08 | Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004052828A1 true WO2004052828A1 (ja) | 2004-06-24 |
Family
ID=32510616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/015694 WO2004052828A1 (ja) | 2002-12-09 | 2003-12-09 | (4e)−5−クロロ−2−イソプロピル−4−ペンテン酸エステルおよびその光学活性体の製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7232925B2 (ja) |
EP (1) | EP1571138B2 (ja) |
JP (1) | JP4645986B2 (ja) |
AT (1) | ATE355263T1 (ja) |
AU (1) | AU2003289250A1 (ja) |
CA (1) | CA2507944C (ja) |
DE (1) | DE60312214T3 (ja) |
ES (1) | ES2281675T5 (ja) |
WO (1) | WO2004052828A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1626093A1 (en) * | 2004-08-11 | 2006-02-15 | Dow Global Technologies Inc. | Process for the production of (S)-5-chloro-2-isopropylpent-4-enoic acid esters |
WO2006041062A1 (ja) * | 2004-10-15 | 2006-04-20 | Asahi Glass Company, Limited | (4e)-5-クロロ-2-イソプロピル-4-ペンテン酸エステルおよびその光学活性体の製造方法 |
WO2006099926A1 (en) * | 2005-03-09 | 2006-09-28 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing enantiopure e-(2s)-alkyl-5-halopent-4-enoic acids and esters |
WO2006117057A1 (en) * | 2005-05-02 | 2006-11-09 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing enantiomerically enriched e-(2s)- and (2r)-alkyl-5-halopent-4-enecarboxylic acids or their esters |
WO2007017018A1 (en) * | 2005-07-25 | 2007-02-15 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing racemic alkyl-5-halopent-4-enecarboxylic acids or -carboxylic esters |
JP2017165679A (ja) * | 2016-03-16 | 2017-09-21 | 信越化学工業株式会社 | 4−メチルオクタン酸エチルの製造方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5182615B2 (ja) * | 2005-12-16 | 2013-04-17 | 旭硝子株式会社 | 光学活性な(4e)−5−クロロ−2−イソプロピル−4−ペンテン酸またはその塩基性アミノ酸塩の製造方法 |
WO2008006394A1 (en) * | 2006-07-14 | 2008-01-17 | F.I.S. Fabbrica Italiana Sintetici S.P.A | Process for the preparation of optically active (4e)-5- halo-2-alkylpent-4-enoic acids and their ester derivatives |
CN110511141B (zh) * | 2019-09-09 | 2022-04-29 | 上海凌凯医药科技有限公司 | 一种丙戊酰脲的合成方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4338326A (en) * | 1979-11-27 | 1982-07-06 | Union Carbide Corporation | Phenoxypyridinemethyl esters of 4-alkenoic acids |
US4492799A (en) * | 1979-07-02 | 1985-01-08 | Union Carbide Corporation | Halo-4-alkenoic acids and their use as pesticidal intermediates |
US4532236A (en) * | 1981-11-27 | 1985-07-30 | Schering Aktiengesellschaft | Certain prostacyclins and their blood-pressure-lowering and thrombocyte-aggregation-inhibiting compositions and methods |
WO2001009079A1 (de) * | 1999-07-29 | 2001-02-08 | Speedel Pharma Ag | 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung |
WO2002008172A1 (en) * | 2000-07-25 | 2002-01-31 | Speedel Pharma Ag | Process for the preparation of substituted octanoyl amides |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3737377C2 (de) * | 1987-11-04 | 1995-07-13 | Huels Chemische Werke Ag | Verfahren zur C-Alkylierung von nicht- und monosubstituierten Malonestern |
BR0209657B1 (pt) † | 2001-05-15 | 2014-10-21 | Speedel Pharma Ag | Processo para a preparação de ésteres de ácidos carboxílicos substituídos por hidrólise enzimática |
-
2003
- 2003-12-09 AT AT03777366T patent/ATE355263T1/de active
- 2003-12-09 EP EP03777366.0A patent/EP1571138B2/en not_active Expired - Lifetime
- 2003-12-09 WO PCT/JP2003/015694 patent/WO2004052828A1/ja active IP Right Grant
- 2003-12-09 AU AU2003289250A patent/AU2003289250A1/en not_active Abandoned
- 2003-12-09 ES ES03777366.0T patent/ES2281675T5/es not_active Expired - Lifetime
- 2003-12-09 CA CA2507944A patent/CA2507944C/en not_active Expired - Fee Related
- 2003-12-09 JP JP2005502360A patent/JP4645986B2/ja not_active Expired - Fee Related
- 2003-12-09 DE DE60312214.0T patent/DE60312214T3/de not_active Expired - Lifetime
-
2005
- 2005-06-08 US US11/147,255 patent/US7232925B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492799A (en) * | 1979-07-02 | 1985-01-08 | Union Carbide Corporation | Halo-4-alkenoic acids and their use as pesticidal intermediates |
US4338326A (en) * | 1979-11-27 | 1982-07-06 | Union Carbide Corporation | Phenoxypyridinemethyl esters of 4-alkenoic acids |
US4532236A (en) * | 1981-11-27 | 1985-07-30 | Schering Aktiengesellschaft | Certain prostacyclins and their blood-pressure-lowering and thrombocyte-aggregation-inhibiting compositions and methods |
WO2001009079A1 (de) * | 1999-07-29 | 2001-02-08 | Speedel Pharma Ag | 2-alkyl-5-halogen-pent-4-encarbonsäuren und deren herstellung |
WO2002008172A1 (en) * | 2000-07-25 | 2002-01-31 | Speedel Pharma Ag | Process for the preparation of substituted octanoyl amides |
Non-Patent Citations (1)
Title |
---|
ARUTYUNYAN V S, ET AL: "KETO LACTONES AND KETO ACIDS. XIX", ARMYANSKII KHIMICHESKII ZHURNAL, vol. 41, no. 8, 1988, pages 522 - 524, XP002976418 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1626093A1 (en) * | 2004-08-11 | 2006-02-15 | Dow Global Technologies Inc. | Process for the production of (S)-5-chloro-2-isopropylpent-4-enoic acid esters |
WO2006033705A1 (en) * | 2004-08-11 | 2006-03-30 | Dow Global Technologies Inc. | Process for the production of (s)-5-chloro-2-isopropylpent-4-enoic acid esters |
WO2006041062A1 (ja) * | 2004-10-15 | 2006-04-20 | Asahi Glass Company, Limited | (4e)-5-クロロ-2-イソプロピル-4-ペンテン酸エステルおよびその光学活性体の製造方法 |
JPWO2006041062A1 (ja) * | 2004-10-15 | 2008-05-15 | 旭硝子株式会社 | (4e)−5−クロロ−2−イソプロピル−4−ペンテン酸エステルおよびその光学活性体の製造方法 |
WO2006099926A1 (en) * | 2005-03-09 | 2006-09-28 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing enantiopure e-(2s)-alkyl-5-halopent-4-enoic acids and esters |
WO2006117057A1 (en) * | 2005-05-02 | 2006-11-09 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing enantiomerically enriched e-(2s)- and (2r)-alkyl-5-halopent-4-enecarboxylic acids or their esters |
AT502257B1 (de) * | 2005-07-25 | 2007-04-15 | Dsm Fine Chem Austria Gmbh | Verfahren zur herstellung von racemischen alkyl-5-halogen-pent-4-en-carbonsäuren bzw. -carbonsäureestern |
WO2007017018A1 (en) * | 2005-07-25 | 2007-02-15 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing racemic alkyl-5-halopent-4-enecarboxylic acids or -carboxylic esters |
JP2009502821A (ja) * | 2005-07-25 | 2009-01-29 | ディーエスエム ファイン ケミカルズ オーストリア エヌエフジー ゲーエムベーハー ウント ツェーオー カーゲー | ラセミ体アルキル−5−ハロペンタ−4−エンカルボン酸または−カルボン酸エステルの調製方法 |
US7550626B2 (en) | 2005-07-25 | 2009-06-23 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Process for preparing racemic alkyl-5-halopent-4-enecarboxylic acids or carboxylic esters |
EA014690B1 (ru) * | 2005-07-25 | 2010-12-30 | Дсм Файн Кемикалс Аустриа Нфг Гмбх Унд Ко Кг | Способ получения рацемических алкил-5-галогенопент-4-енкарбоновых кислот или алкил-5-галогенопент-4-енкарбоновых эфиров |
CN101233097B (zh) * | 2005-07-25 | 2011-06-08 | Dsm精细化学奥地利Nfg两合公司 | 外消旋烷基-5-卤代戊-4-烯酸或其酯的制备方法 |
JP2017165679A (ja) * | 2016-03-16 | 2017-09-21 | 信越化学工業株式会社 | 4−メチルオクタン酸エチルの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
DE60312214T3 (de) | 2015-02-26 |
EP1571138A1 (en) | 2005-09-07 |
ES2281675T5 (es) | 2015-01-22 |
CA2507944A1 (en) | 2004-06-24 |
ATE355263T1 (de) | 2006-03-15 |
JPWO2004052828A1 (ja) | 2006-04-13 |
JP4645986B2 (ja) | 2011-03-09 |
DE60312214D1 (de) | 2007-04-12 |
EP1571138A4 (en) | 2005-12-07 |
US20050228193A1 (en) | 2005-10-13 |
AU2003289250A1 (en) | 2004-06-30 |
ES2281675T3 (es) | 2007-10-01 |
EP1571138B2 (en) | 2014-12-17 |
DE60312214T2 (de) | 2007-11-15 |
CA2507944C (en) | 2012-04-17 |
EP1571138B1 (en) | 2007-02-28 |
US7232925B2 (en) | 2007-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9061991B2 (en) | Method for producing 1-amino-1-alkoxycarbonyl-2-vinylcyclopropane | |
US7232925B2 (en) | Process for producing (4E)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof | |
JPH1081648A (ja) | エナンチオマー富化され、3級炭化水素基でα−モノ置換されたマロン酸モノエステル又はその塩及びその製法 | |
JP4252803B2 (ja) | 酵素加水分解による置換カルボン酸エステルの調製方法 | |
US20070191630A1 (en) | Processes for producing (4e)-5-chloro-2-isopropyl-4-pentenoate and optically active form thereof | |
EP0679629B1 (fr) | Procédé de préparation d'un acide alpha-(hydroxyphenoxy)-alcanecarboxylique optiquement actif et de ses dérivés | |
WO2020255164A1 (en) | A chemo-enzymatic process for the preparation of homopropargylic alcohol | |
JP4043810B2 (ja) | 光学活性3−クロロカルボン酸エステルの製造方法 | |
JP6287528B2 (ja) | 光学活性3,3−ジフルオロ乳酸誘導体の製造方法 | |
JP2007254293A (ja) | α−メチレン−β−アルキル−γ−ブチロラクトンの製造法 | |
JP2002128734A (ja) | ベンジルtert−ブチルマロネートの製造方法 | |
JPH06192221A (ja) | 光学活性な1−(4−t−ブチルフェニル)−5−オキソ−3−ピロリジンカルボン酸の製造方法 | |
JP2004350522A (ja) | 光学活性エステルおよび/または光学活性カルボン酸の製造方法 | |
JP2008295302A (ja) | 光学活性エステル誘導体および/または光学活性カルボン酸の製造方法 | |
WO2007066532A1 (ja) | テトラフルオロテレフタル酸ジフルオライドの製造方法 | |
US20040049067A1 (en) | Process for the enantioselective synthesis of propargyl alcohol derivatives of R configuration from the racemic mixtures thereof | |
JP2006502201A (ja) | 改良されたシンセトン合成 | |
JP2002128735A (ja) | 高純度ヒドロキシマロン酸ジエステルの製造法 | |
JP2002088057A (ja) | 光学活性な3−ヒドロキシピロリジン類の製造方法 | |
JP2002179625A (ja) | 2,4,5−トリハロゲノ−3−メチル−6−ニトロ安息香酸類の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005502360 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2507944 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003777366 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11147255 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003777366 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003777366 Country of ref document: EP |